Clinical Trial Update: A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area [Phase 1]

View source ↗

Summary

This Phase 1 double-blind, placebo-controlled, dose-escalation study evaluated the safety and immunogenicity of the dmLT adjuvant delivered via oral, sublingual…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Escherichia Coli Gastroenteritis

Drugs mentioned

• dmLT (double-mutant Escherichia coli heat-labile toxin (dmLT))

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Gastroenteritis Escherichia Coli, Immunisation | Phase 1 | Status: TERMINATED | Results posted: 2022-01-18